Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE

Key Points

• Dimensional Fund Advisors cut its Fate Therapeutics stake by 44% in the first quarter, selling 693,688 shares and retaining 883,790 shares worth approximately $1.06 million. Institutional investors and hedge funds collectively own 97.54% of the company.
• Fate Therapeutics reported quarterly EPS of -$0.25, in line with analyst expectations, while revenue of $2.08 million exceeded forecasts. The company remains unprofitable, with analysts expecting a full-year EPS loss of $1.04.
• Analyst sentiment is mixed, with four Buy, three Hold and one Sell rating; the average rating is Hold and the average price target is $5.90, compared with shares opening at $2.57.

Dimensional Fund Advisors LP reduced its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 44.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 883,790 shares of the biopharmaceutical company's stock after selling 693,688 shares during the period. Dimensional Fund Advisors LP owned about 0.76% of Fate Therapeutics worth $1,060,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in FATE. Renaissance Technologies LLC raised its stake in Fate Therapeutics by 87.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,360,881 shares of the biopharmaceutical company's stock valued at $2,320,000 after purchasing an additional 1,098,366 shares during the last quarter. Two Sigma Investments LP raised its stake in Fate Therapeutics by 294.4% during the third quarter. Two Sigma Investments LP now owns 900,757 shares of the biopharmaceutical company's stock worth $1,135,000 after purchasing an additional 672,352 shares during the period. AQR Capital Management LLC raised its stake in Fate Therapeutics by 296.4% during the first quarter. AQR Capital Management LLC now owns 585,025 shares of the biopharmaceutical company's stock worth $462,000 after purchasing an additional 437,423 shares during the period. Jane Street Group LLC boosted its holdings in Fate Therapeutics by 631.4% in the 2nd quarter. Jane Street Group LLC now owns 465,820 shares of the biopharmaceutical company's stock valued at $522,000 after purchasing an additional 402,129 shares during the last quarter. Finally, Man Group plc acquired a new position in Fate Therapeutics in the 3rd quarter valued at about $277,000. 97.54% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Fate Therapeutics

In other news, insider Cindy Tahl sold 25,590 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $1.88, for a total value of $48,109.20. Following the completion of the sale, the insider directly owned 628,155 shares of the company's stock, valued at approximately $1,180,931.40. This represents a 3.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.74% of the company's stock.

Fate Therapeutics Price Performance

Shares of FATE opened at $2.57 on Friday. Fate Therapeutics, Inc. has a 1-year low of $0.93 and a 1-year high of $3.23. The stock has a market cap of $299.56 million, a PE ratio of -2.45 and a beta of 2.52. The firm has a fifty day moving average price of $2.50 and a 200 day moving average price of $1.86.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.25) EPS for the quarter, hitting analysts' consensus estimates of ($0.25). The business had revenue of $2.08 million for the quarter, compared to analysts' expectations of $1.94 million. Fate Therapeutics had a negative return on equity of 60.87% and a negative net margin of 1,941.09%. As a group, equities analysts expect that Fate Therapeutics, Inc. will post -1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

FATE has been the subject of several analyst reports. Wells Fargo & Company increased their price target on shares of Fate Therapeutics from $2.50 to $3.50 and gave the company an "equal weight" rating in a research note on Friday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Fate Therapeutics in a research report on Friday, August 7th. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Monday, June 8th. Wedbush restated an "outperform" rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Friday. Finally, Jefferies Financial Group set a $4.00 target price on Fate Therapeutics in a research report on Tuesday, May 19th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $5.90.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source